Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Biochim Biophys Acta ; 1813(10): 1836-44, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21745501

ABSTRACT

The Src-homology 3 (SH3) domain is one of the most frequent protein recognition modules (PRMs), being represented in signal transduction pathways and in several pathologies such as cancer and AIDS. Grb2 (growth factor receptor-bound protein 2) is an adaptor protein that contains two SH3 domains and is involved in receptor tyrosine kinase (RTK) signal transduction pathways. The HIV-1 transactivator factor Tat is required for viral replication and it has been shown to bind directly or indirectly to several host proteins, deregulating their functions. In this study, we show interaction between the cellular factor Grb2 and the HIV-1 trans-activating protein Tat. The binding is mediated by the proline-rich sequence of Tat and the SH3 domain of Grb2. As the adaptor protein Grb2 participates in a wide variety of signaling pathways, we characterized at least one of the possible downstream effects of the Tat/Grb2 interaction on the well-known IGF-1R/Raf/MAPK cascade. We show that the binding of Tat to Grb2 impairs activation of the Raf/MAPK pathway, while potentiating the PKA/Raf inhibitory pathway. The Tat/Grb2 interaction affects also viral function by inhibiting the Tat-mediated transactivation of HIV-1 LTR and viral replication in infected primary microglia.


Subject(s)
GRB2 Adaptor Protein/metabolism , HIV Infections/virology , HIV-1/physiology , Microglia/physiology , src Homology Domains , tat Gene Products, Human Immunodeficiency Virus/metabolism , Amino Acid Sequence , Cells, Cultured , Extracellular Signal-Regulated MAP Kinases/metabolism , GRB2 Adaptor Protein/chemistry , GRB2 Adaptor Protein/physiology , HIV Infections/metabolism , HIV Infections/pathology , HIV-1/metabolism , Host-Pathogen Interactions/physiology , Humans , Microglia/metabolism , Microglia/pathology , Microglia/virology , Molecular Sequence Data , Protein Binding , Signal Transduction , Virus Replication/physiology , tat Gene Products, Human Immunodeficiency Virus/physiology
2.
J Cell Physiol ; 226(7): 1763-70, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21506108

ABSTRACT

Inhibitor of differentiation-1 (Id-1) is a member of helix-loop-helix (HLH) family of proteins that regulate gene transcription through their inhibitory binding to basic-HLH transcription factors. Similarly to other members of this family, Id-1 is involved in the repression of cell differentiation and activation of cell growth. The dual function of Id-1, inhibition of differentiation, and stimulation of cell proliferation, might be interdependent, as cell differentiation is generally coupled with the exit from the cell cycle. Fibroblast growth factor-2 (FGF-2) has been reported to play multiple roles in different biological processes during development of the central nervous system (CNS). In addition, FGF-2 has been described to induce "neuronal-like" differentiation and trigger apoptosis in neuroblastoma SK-N-MC cells. Although regulation of Id-1 protein by several mitogenic factors is well-established, little is known about the role of FGF-2 in the regulation of Id-1. Using human neuroblastoma cell line, SK-N-MC, we found that treatment of these cells with FGF-2 resulted in early induction of both Id-1 mRNA and protein. The induction occurs within 1 h from FGF-2 treatment and is mediated by ERK1/2 pathway, which in turn stimulates expression of the early growth response-1 (Egr-1) transcription factor. We also demonstrate direct interaction of Egr-1 with Id-1 promoter in vitro and in cell culture. Finally, inhibition of Id-1 expression results in G(2) /M accumulation of FGF-2-treated cells and delayed cell death.


Subject(s)
Apoptosis , Brain Neoplasms/metabolism , Early Growth Response Protein 1/metabolism , Fibroblast Growth Factor 2/metabolism , Inhibitor of Differentiation Protein 1/metabolism , Neuroblastoma/metabolism , Binding Sites , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Cell Cycle , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Inhibitor of Differentiation Protein 1/genetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Neuroblastoma/genetics , Neuroblastoma/pathology , Promoter Regions, Genetic , RNA Interference , RNA, Messenger/metabolism , Recombinant Proteins/metabolism , Time Factors , Transfection , Up-Regulation
3.
FASEB J ; 24(7): 2292-300, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20181935

ABSTRACT

MicroRNA-mediated regulation of gene expression appears to be involved in a variety of cellular processes, including development, differentiation, proliferation, and apoptosis. Mir-146a is thought to be involved in the regulation of the innate immune response, and its expression is increased in tissues associated with chronic inflammation. Among the predicted gene targets for mir-146a, the chemokine CCL8/MCP-2 is a ligand for the CCR5 chemokine receptor and a potent inhibitor of CD4/CCR5-mediated HIV-1 entry and replication. In the present study, we have analyzed changes in the expression of mir-146a in primary human fetal microglial cells upon infection with HIV-1 and found increased expression of mir-146a. We further show that CCL8/MCP-2 is a target for mir-146a in HIV-1 infected microglia, as overexpression of mir-146a prevented HIV-induced secretion of MCP-2 chemokine. The clinical relevance of our findings was evaluated in HIV-encephalitis (HIVE) brain samples in which decreased levels of MCP-2 and increased levels of mir-146a were observed, suggesting a role for mir-146a in the maintenance of HIV-mediated chronic inflammation of the brain.


Subject(s)
Chemokine CCL8/antagonists & inhibitors , HIV Infections/etiology , HIV-1/pathogenicity , MicroRNAs/genetics , Microglia/virology , Cells, Cultured , Encephalitis, Viral/pathology , Gene Expression Regulation/immunology , HIV Infections/genetics , HIV Infections/immunology , Humans , Inflammation/virology
4.
Biochim Biophys Acta ; 1793(2): 378-87, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19022302

ABSTRACT

HIV-Encephalopathy (HIVE) is a common neurological disorder associated with HIV-1 infection and AIDS. The activity of the HIV trans-activating protein Tat is thought to contribute to neuronal pathogenesis. While Tat proteins from primary virus isolates consist of 101 or more amino acids, 72 and 86 amino acids forms of Tat are commonly used for in vitro studies. Although Tat72 contains the minimal domain required for viral replication, other activities of Tat appear to vary according to its length, sub-cellular localization, cell type and the stage of cellular differentiation. In this study, we investigated the stability of intracellular Tat101 during proliferation and differentiation of neuronal cells in culture. We have utilized rat neuronal progenitors as a model of neuronal cell proliferation and differentiation, as well as rat primary cortical neurons as a model of fully differentiated cells. Our results indicate that, upon internalization, Tat101 was degraded more rapidly in proliferating cells than in cells which either underwent neuronal differentiation or were fully differentiated. Intracellular degradation of Tat was prevented by the calpain 1 inhibitor, ALLN, in both proliferating and differentiated cells. Inhibition of calpain 1 by calpastatin peptide also prevented Tat cleavage. In vitro calpain digestion and mass spectrometry analysis further demonstrated that the sequence of Tat sensitive to calpain cleavage was located in the C-terminus of this viral protein, between amino acids 68 and 69. Moreover, cleavage of Tat101 by calpain 1 increased neurotoxic effect of this viral protein and presence of the calpain inhibitor protected neuronal cells from Tat-mediated toxicity.


Subject(s)
Calpain/metabolism , Neurons/drug effects , Neurons/metabolism , tat Gene Products, Human Immunodeficiency Virus/chemistry , tat Gene Products, Human Immunodeficiency Virus/toxicity , Amino Acid Sequence , Animals , Cell Differentiation/drug effects , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Proliferation/drug effects , Cells, Cultured , Cerebral Cortex/cytology , Cerebral Cortex/embryology , Enzyme Inhibitors/pharmacology , Intracellular Space/drug effects , Intracellular Space/metabolism , Leupeptins/pharmacology , Molecular Sequence Data , Neurons/cytology , Protein Processing, Post-Translational , Protein Stability/drug effects , Protein Transport/drug effects , Rats , Stem Cells/cytology , Stem Cells/drug effects , Stem Cells/metabolism , Subcellular Fractions/drug effects , Subcellular Fractions/metabolism , tat Gene Products, Human Immunodeficiency Virus/metabolism
5.
J Cell Physiol ; 216(3): 764-70, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18381601

ABSTRACT

MicroRNAs (miRs) are short endogenous RNAs that regulate gene expression by incomplete pairing with messenger RNAs. An increasing number of studies show that mammalian microRNAs play fundamental roles in various aspects of cellular function including differentiation, proliferation, and cell death. Recent findings demonstrating the presence of microRNAs in mature neuronal dendrites suggest their possible involvement in controlling local protein translation and synaptic function. HIV-1 Encephalopathy (HIVE) is a manifestation of HIV-1 infection that often results in neuronal damage and dysfunction. While neurons are rarely, if ever, infected by HIV-1, they are exposed to cytotoxic viral and cellular factors including the HIV-1 transactivating factor Tat. In this study, we show that Tat deregulates expression levels of selected microRNAs, including the neuronal mir-128, in primary cortical neurons. We further show that mir-128a inhibits expression of the pre-synaptic protein SNAP25, whereas the anti-mir-128a partially restores Tat/mir-128a-induced downregulation of SNAP25 expression. Altogether, our data provide a novel mechanism by which HIV-Tat perturbs neuronal activity.


Subject(s)
MicroRNAs/metabolism , Neurons/metabolism , Synaptosomal-Associated Protein 25/metabolism , tat Gene Products, Human Immunodeficiency Virus/metabolism , Animals , Cells, Cultured , Cerebral Cortex/cytology , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Humans , Mice , Mice, Inbred C57BL , MicroRNAs/genetics , Neurons/cytology , Rats , Reproducibility of Results , Synaptosomal-Associated Protein 25/genetics , tat Gene Products, Human Immunodeficiency Virus/genetics
6.
Leuk Lymphoma ; 48(10): 2014-21, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17917969

ABSTRACT

Vascular Endothelial Growth Factor (VEGF)-D is a member of the VEGF family of angiogenic growth factors that activate the Vascular Endothelial Growth Factor Receptor (VEGFR)-2 and VEGFR-3, which are mainly expressed in blood and lymphatic vessels. Here we have analyzed by using monoclonal antibodies, the expression of VEGF-D and its cognate receptor VEGFR-3 in normal and pathologic bone marrow and lymph node biopsies. This analysis revealed that VEGF-D is expressed in B cells of the germinal centers, scattered B and T blasts, myeloid progenitors, acute leukemia, several types of non Hodgkin lymphoma, and classical Hodgkin's lymphoma. In normal tissues VEGFR-3 was only expressed in fenestrated capillaries of bone marrow and in lymphatic vessels of lymph nodes, while in VEGF-D expressing tumors newly formed vessels, but not malignant cells, showed high VEGFR-3 expression. These data suggest that VEGF-D could contribute to leukemia and lymphoma growth via the induction of angiogenesis in bone marrow and lymphoid tissues.


Subject(s)
Gene Expression Regulation, Leukemic , Gene Expression Regulation, Neoplastic , Hematopoietic Stem Cells/metabolism , Lymphocytes/metabolism , Vascular Endothelial Growth Factor D/biosynthesis , Antibodies, Monoclonal/chemistry , Biopsy , Bone Marrow Cells/metabolism , Cell Line, Tumor , HL-60 Cells , Humans , K562 Cells , Lymph Nodes/pathology , Vascular Endothelial Growth Factor Receptor-2/metabolism , Vascular Endothelial Growth Factor Receptor-3/biosynthesis , Vascular Endothelial Growth Factor Receptor-3/metabolism
7.
J Neurosci Res ; 85(11): 2360-73, 2007 Aug 15.
Article in English | MEDLINE | ID: mdl-17593555

ABSTRACT

Tumor necrosis factor-alpha (TNFalpha) released in the brain by HIV-activated macrophages/microglia is suspected to compromise neuronal survival. Previously, we have demonstrated that activated receptor for insulin-like growth factor I (IGF-IR) protects neurons from TNFalpha-induced neuronal damage (Wang et al. [ 2006] J. Neurosci. Res. 83:7-18). Because TNFalpha triggers phosphorylation of insulin receptor substrate 1 (IRS-1) on serine residues (pS-IRS-1; Rui et al. [ 2001] J. Clin. Invest. 107:181-189), and pS-IRS-1 binds integrins (Reiss et al. [ 2001] Oncogene 20:490-500), we asked how these events affect neuronal processes. We show that beta1-integrin and pS-IRS-1 colocalize in PC12 cells and in primary cortical neurons. TNFalpha treatment elevated membrane-associated pS-IRS-1, enhanced pS-IRS-1 interaction with beta1-integrin, and attenuated cell attachment to collagen IV. In contrast, IGF-I inhibited pS-IRS-1-beta1-integrin complexes and improved cell attachment. The domain of IRS-1 involved in beta1-integrin binding mapped between amino acids 426 and 740, and the expression of 426-740/IRS-1 mutant attenuated neuronal outgrowth. Our results indicate that TNFalpha facilitates the interaction of pS-IRS-1 and beta1-integrin and destabilizes neuronal processes. IGF-I counteracts TNFalpha-mediated accumulation of pS-IRS-1-beta1-integrin complexes supporting the stability of neuronal processes.


Subject(s)
Integrin beta1/metabolism , Neurons/metabolism , Phosphoproteins/metabolism , Serine/metabolism , Animals , Blotting, Western , Cell Adhesion/physiology , Cells, Cultured , Cerebral Cortex/metabolism , Fluorescent Antibody Technique , Immunoprecipitation , Insulin Receptor Substrate Proteins , Insulin-Like Growth Factor I/metabolism , Membrane Microdomains/metabolism , Phosphoproteins/chemistry , Phosphorylation , Protein Binding , Rats , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...